Saccharomyces cerevisiae Beta-Glucan (Wellmune): The Immune Yeast Fibre

← Back to articles

Beta-glucans are a chemically diverse class of polysaccharide fibres, and their effects differ markedly by source and structure — a fact the supplement aisle frequently blurs. Oat beta-glucan (linear, 1,3/1,4-linked) carries an FDA cholesterol-lowering health claim and works mechanically, by binding bile acids in the gut. Yeast beta-glucan from Saccharomyces cerevisiae (a 1,3 backbone with 1,6 branches) is a different molecule with a different job: it does not lower cholesterol, but its branched structure is recognized by innate-immune receptors. The branded ingredient Saccharomyces cerevisiae beta-glucan sold as Wellmune (originally Biothera, now Kerry) has the largest set of randomized trials for preventing upper respiratory tract infections (URTIs). The honest read of that evidence is that it is real but modest, heavily concentrated in athletes and stressed adults, and substantially funded by the ingredient's own manufacturer — which is exactly why it deserves a careful look rather than the "clinically proven immune support" framing on the label.

The upper respiratory infection trial evidence

Several randomized, placebo-controlled trials have tested 250–500 mg/day of yeast beta-glucan over the cold-and-flu season. The pattern is consistent but the magnitude is small. In Shawn Talbott's 12-week trial of 77 women with moderate psychological stress, the Wellmune group reported markedly fewer self-reported upper-respiratory symptoms than placebo (10% vs 29%) plus better mood scores; that study was authored by a supplement-industry consultant. Two later trials in Austin Marathon runners (357 and, in a second report, 278 participants) found that the per-protocol beta-glucan groups had fewer URTI symptomatic days and lower symptom severity (notably nasal discharge and sore throat) — but, importantly, no reduction in the number or duration of infections themselves; both were run by Biofortis, a contract research organization, on a beverage matrix.

The single most independent trial is also the most sobering. A 2017 study by Fuller and colleagues at the University of Southampton, in 100 community-dwelling adults aged 50–70, found that medically confirmed URTIs were numerically lower with Wellmune (17 vs 28 episodes) but the difference was not statistically significant (odds ratio 0.55, 95% CI 0.24–1.26, P=0.149). There was only a non-significant trend toward fewer symptom days, and symptom severity did not differ. In other words, when the people running the trial had no commercial stake in the ingredient, the headline benefit shrank to a trend. Taken together, the fair conclusion is that yeast beta-glucan may modestly reduce how bad and how long URTI symptoms feel, with weaker and inconsistent evidence that it prevents infections outright.

The dectin-1 mechanism

The mechanistic story is genuinely interesting and is the reason researchers keep testing this molecule. The 1,3/1,6-branched yeast glucan is a ligand for dectin-1 (CLEC7A), a pattern-recognition receptor on innate immune cells such as macrophages, neutrophils and dendritic cells. Engaging dectin-1 triggers pro-inflammatory cytokine production and has been linked to "trained immunity" — a metabolic and epigenetic reprogramming of innate immune cells that primes them to respond faster to a later microbial challenge. This is a more specific innate-priming pathway than the broad effects loosely attributed to products like colostrum or echinacea. The caveat is that most of this mechanistic work uses purified glucans in cell or animal models — for example, particulate (but not soluble) yeast beta-glucan upregulates costimulatory molecules and cytokines via dectin-1 in monocytes — and a plausible mechanism does not by itself prove a clinically meaningful benefit in a person taking a capsule.

Why athletes dominate the data

Athletic and stressed populations are over-represented in the positive trials, probably for a real physiological reason: heavy endurance exercise transiently dampens parts of innate immunity and raises short-term URTI risk, creating a window in which a prevention effect is easier to detect. That makes endurance athletes a sensible test population, but it also means the results may not transfer cleanly to a sedentary adult with an ordinary infection risk. The two marathon trials are the clearest example — benefits showed up in symptom-day and severity measures, not in whether runners got sick at all.

Dose, form, and practical use

Trial-effective doses cluster at 250–500 mg/day of standardized extract, taken daily through the higher-risk season; Wellmune is the specific tested form. Because the proposed benefit is preventive and tied to ongoing intake, several weeks of daily use is the realistic test, not a single dose at the first sniffle. Tolerability is excellent: yeast beta-glucan is well tolerated in the trials, including in older adults, with no consistent safety signal at these doses. The one sensible precaution is in people on significant immunosuppression (for example after organ transplant or during certain immune-targeted therapies) — an innate-immune-priming agent has not been studied in that context, so it should not be added without specialist input.

What it doesn't do

Yeast beta-glucan does not lower cholesterol — that is oat beta-glucan, a different molecule. It is not the injectable, pharmaceutical-grade beta-glucan studied as an adjuvant in cancer, which is a separate class entirely. And it does not deliver a dramatic acute "immune boost"; the realistic benefit is a modest reduction in URTI symptom burden over a season of daily use. Given that the strongest claims come from manufacturer-linked studies and the most independent trial was negative on its primary endpoint, it is best viewed as a low-risk, possibly-helpful option for people with high infection exposure — not a proven shield against colds.

Sources

1. Fuller R, Moore MV, Lewith G, et al. "Yeast-derived β-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults." Nutrition, 2017;39–40:30–35. PMID 28606567.
2. Talbott SM, Talbott JA. "Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women." Journal of the American College of Nutrition, 2012;31(4):295–300 (author was a supplement-industry consultant). PMID 23378458.
3. Mah E, Kaden VN, Kelley KM, Liska DJ. "Beverage containing dispersible yeast β-glucan decreases cold/flu symptomatic days after intense exercise: a randomized controlled trial." Journal of Dietary Supplements, 2018;17(2):200–210 (industry-funded; Biofortis/Mérieux NutriSciences). PMID 30380356.
4. Mah E, Kaden VN, Kelley KM, Liska DJ. "Soluble and insoluble yeast β-glucan differentially affect upper respiratory tract infection in marathon runners: a double-blind, randomized placebo-controlled trial." Journal of Medicinal Food, 2019;23(4):416–419 (industry-funded). PMID 31573387.
5. Talbott S, Talbott J. "Effect of BETA 1,3/1,6 GLUCAN on upper respiratory tract infection symptoms and mood state in marathon athletes." Journal of Sports Science & Medicine, 2009;8(4):509–515. PMID 24149590.
6. Pedro ARV, Lima T, Fróis-Martins R, et al. "Dectin-1-mediated production of pro-inflammatory cytokines induced by yeast β-glucans in bovine monocytes." Frontiers in Immunology, 2021;12:689879. PMID 34122455.